Adult Dosing

Immunization

• 0.5 mL SC x1 to the individuals known to have susceptible risk

Pediatric Dosing

Immunization

• 0.5 mL SC at 12-15 months of age, followed by revaccination with M-M-R II prior to elementary school entry
• Children first vaccinated >12 months of age should receive another dose between 12-15 months of age followed by revaccination with M-M-R II prior to elementary school entry

[Outline]

• Adult Dosing
• Pediatric Dosing

• Vaccination against measles in persons 12 months of age or older, may give to infants 6-12 months of age during outbreak of measles

• Hypersensitivity to any of the ingredients of the product
• Hypersensitivity to neomycin
• Pregnancy or planned pregnancy within 3 months
• Febrile respiratory illness or other active febrile infection
• Patients receiving immunosuppressive therapy
• Blood dyscrasias, leukemia, lymphomas of any type, or other malignant neoplasms affecting the bone marrow or lymphatic systems
• Primary and acquired immunodeficiency states
• Family history of congenital or hereditary immunodeficiency
• Active untreated tuberculosis

• N/A

Renal Dose Adjustment

• Renal impairment: Dose adjustments not defined

Hepatic Dose Adjustment

• Hepatic impairment: Dose adjustments not defined

• Measles vaccine should be used cautiously in any condition in which stress due to fever should be avoided such as history of cerebral injury, individual or family histories of convulsions. Physician should be alert to the temperature elevation which may occur following vaccination
• Measles vaccine contains albumin, a derivative of human blood and may carry a risk of transmission of viral diseases. However because of effective donor screening and product manufacturing processes this risk is extremely remote
• Live measles vaccine is produced in chick embryo cell culture, hence can cause anaphylactic, anaphylactoid or other immediate reactions in a person hypersensitive to egg. Use with extreme caution in these patients with adequate emergency treatment on hand
• Do not administer to the person who has experienced anaphylactic reactions to topically or systemically administered neomycin. However history of contact dermatitis to neomycin is not a contraindication to receiving measles
• Adequate emergency treatment, including epinephrine injection (1:1000), should be available for immediate use in case anaphylactic or anaphylactoid reaction occurs
• Take special care that injection does not enter a blood vessel
• The expected immune response will not be obtained if vaccine is administered to immunocompromised persons
• Delay the vaccination for 3 months or longer following blood or plasma transfusions, or administration of immune globulin (human)
• Attenuated measles virus vaccine live may result in a temporary depression of tuberculin skin sensitivity. Hence perform tuberculin test either before or simultaneously with measles virus vaccine
• Live measles vaccination in children under treatment for tuberculosis, does not exacerbate the disease. However, individuals with active untreated tuberculosis should not be vaccinated

Cautions: Use cautiously in

• History of cerebral injury
• Individual or family histories of convulsions
• Hypersensitivity to egg protein
• Thrombocytopenia

Pregnancy Category:C

Breastfeeding: It is unknown whether measles vaccine virus is secreted in human milk. As many drugs are excreted in human milk manufacturer advises caution

• CNS: Encephalitis, encephalopathy, syncope, headache, dizziness, irritability, measles inclusion body encephalitis, subacute sclerosing panencephalitis, Guillain-Barré syndrome, febrile convulsions, afebrile convulsions or seizures, ataxia, ocular palsies
• CV: Vasculitis
• GI: Diarrhea, vomiting, nausea
• HEMA: Thrombocytopenia, purpura, lymphadenopathy, leukocytosis
• IMMU: Anaphylaxis and anaphylactoid reactions, angioneurotic edema, bronchial spasm
• MUSC: Arthralgia, myalgia
• RESP: Pneumonitis, cough, rhinitis
• DERM: Stevens-Johnson syndrome, erythema multiforme, urticaria, rash
• LOCAL: Burning/stinging at injection site, wheal and flare, redness, swelling, vesiculation at injection site
• EENT: Nerve deafness, otitis media, retinitis, optic neuritis, papillitis, retrobulbar neuritis, conjunctivitis
• MISC: Panniculitis, atypical measles, fever, malaise

• Vaccine; induce measles hemagglutination-inhibition (HI) antibodies
• Metabolism: Other
• Excretion: Other
• Half-life: Unknown

US Trade Name(s)

• Attenuvax (Discontinued)

US Availability

Attenuvax

• PWDR for INJ: 0.5 mL (single use vial)

Canadian Trade Name(s)

• N/A

Canadian Availability

• N/A

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

[Outline]

Allergy & Immunology

Vaccines

Viral

Infectious Disease

Vaccines

Viral